Noticias de dinero

Eli Lilly taps Amazon Pharmacy to help deliver Zepbound, other drugs

Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021.  Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program.  Starting Wednesday,

READ MORE
Noticias de dinero

Eli Lilly Alzheimer’s drug FDA approval delayed

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty

READ MORE
Noticias de dinero

Novo Nordisk, Eli Lilly are tackling supply issues

Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments.  The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said

READ MORE
Noticias de dinero

Novo Nordisk, Eli Lilly tackle weight loss drug supply woes

Good afternoon! All eyes are on Novo Nordisk and Eli Lilly again as Wall Street looks for signs that they can address one of the biggest hurdles they faced last year. Neither company has enough supply to meet the insatiable demand for their weight loss and diabetes drugs.  One month into 2024, the two drugmakers still haven’t fully resolved those supply issues.

READ MORE
Noticias de dinero

Eli Lilly (LLY) earnings Q4 2023

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020.  Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro.

READ MORE